Atossa Set to Join Russell 3000® Index Effective June 28, 2024 [Yahoo! Finance]
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: Yahoo! Finance
inclusion in the Russell 3000 ® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "Atossa's inclusion in the Russell 3000 ® Index is our latest milestone, adding to what has already been a transformational year for the Company,” said Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer. “Among other progress, we presented extremely encouraging monotherapy data at the American Association for Cancer Research (AACR) Annual Meeting and initiated a Phase 2 study investigating the combination of our proprietary (Z)-endoxifen and abemaciclib (VERZENIO ® ), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company. And, later this year, we e
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.25 to $6.50. They now have a "buy" rating on the stock.MarketBeat
- Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast CancerGlobeNewswire
- Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Atossa Therapeutics Granted Additional Patent Protection for EndoxifenGlobeNewswire
ATOS
Earnings
- 8/12/24 - In-Line
ATOS
Sec Filings
- 8/12/24 - Form 10-Q
- 8/12/24 - Form 8-K
- 7/2/24 - Form 8-K
- ATOS's page on the SEC website